<DOC>
	<DOCNO>NCT00559117</DOCNO>
	<brief_summary>Aim study evaluate safety find maximal tolerate dose VB-111 Patients Advanced Metastatic Cancer</brief_summary>
	<brief_title>A Phase I Study Assess Safety Distribution VB-111 Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description>Nine Cohorts dose escalate VB-111 complete total 56 subject enrol .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patients ≥18 year age Histologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective . For Cohort 8 , malignancy include NET RCC . Karnofsky performance status ≥70 % Patients adequate hematological profile Patients adequate renal function Males Females childbearing potential must utilize standard contraception method Ability understand willingness sign write informed consent document . Pregnant breastfeeding patient Patients , suffer acute cardiac event within last 12 month Patients active vascular disease , either myocardial peripheral Patients proliferative and/or vascular retinopathy Patients know liver disease ( alcoholic , drug/toxin induce , genetic , autoimmune ) Patients known CNS metastatic disease Patients test positive one follow virus : HIV , HBV HCV Patients receive chemotherapy radiotherapy within last 4 week enrolment Patients undergone major surgery within last 4 week enrolment Patients may receive antiangiogenic therapy within previous 8 week enrolment . Patients may receive investigational agent within 4 week enrolment . Patients ongoing requirement immunosuppressive treatment , include use glucocorticoid cyclosporin , history chronic use medication within last 4 week enrolment Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>